493 related articles for article (PubMed ID: 25636082)
1. NR2F1 controls tumour cell dormancy via SOX9- and RARβ-driven quiescence programmes.
Sosa MS; Parikh F; Maia AG; Estrada Y; Bosch A; Bragado P; Ekpin E; George A; Zheng Y; Lam HM; Morrissey C; Chung CY; Farias EF; Bernstein E; Aguirre-Ghiso JA
Nat Commun; 2015 Jan; 6():6170. PubMed ID: 25636082
[TBL] [Abstract][Full Text] [Related]
2. NR2F1 stratifies dormant disseminated tumor cells in breast cancer patients.
Borgen E; Rypdal MC; Sosa MS; Renolen A; Schlichting E; Lønning PE; Synnestvedt M; Aguirre-Ghiso JA; Naume B
Breast Cancer Res; 2018 Oct; 20(1):120. PubMed ID: 30322396
[TBL] [Abstract][Full Text] [Related]
3. Phenotypic heterogeneity of disseminated tumour cells is preset by primary tumour hypoxic microenvironments.
Fluegen G; Avivar-Valderas A; Wang Y; Padgen MR; Williams JK; Nobre AR; Calvo V; Cheung JF; Bravo-Cordero JJ; Entenberg D; Castracane J; Verkhusha V; Keely PJ; Condeelis J; Aguirre-Ghiso JA
Nat Cell Biol; 2017 Feb; 19(2):120-132. PubMed ID: 28114271
[TBL] [Abstract][Full Text] [Related]
4. An NR2F1-specific agonist suppresses metastasis by inducing cancer cell dormancy.
Khalil BD; Sanchez R; Rahman T; Rodriguez-Tirado C; Moritsch S; Martinez AR; Miles B; Farias E; Mezei M; Nobre AR; Singh D; Kale N; Sproll KC; Sosa MS; Aguirre-Ghiso JA
J Exp Med; 2022 Jan; 219(1):. PubMed ID: 34812843
[TBL] [Abstract][Full Text] [Related]
5. Long non-coding RNA NR2F1-AS1 induces breast cancer lung metastatic dormancy by regulating NR2F1 and ΔNp63.
Liu Y; Zhang P; Wu Q; Fang H; Wang Y; Xiao Y; Cong M; Wang T; He Y; Ma C; Tian P; Liang Y; Qin LX; Yang Q; Yang Q; Liao L; Hu G
Nat Commun; 2021 Sep; 12(1):5232. PubMed ID: 34475402
[TBL] [Abstract][Full Text] [Related]
6. Osteoblast-Secreted Factors Mediate Dormancy of Metastatic Prostate Cancer in the Bone via Activation of the TGFβRIII-p38MAPK-pS249/T252RB Pathway.
Yu-Lee LY; Yu G; Lee YC; Lin SC; Pan J; Pan T; Yu KJ; Liu B; Creighton CJ; Rodriguez-Canales J; Villalobos PA; Wistuba II; de Nadal E; Posas F; Gallick GE; Lin SH
Cancer Res; 2018 Jun; 78(11):2911-2924. PubMed ID: 29514796
[TBL] [Abstract][Full Text] [Related]
7. Tumor removal limits prostate cancer cell dissemination in bone and osteoblasts induce cancer cell dormancy through focal adhesion kinase.
Liu R; Su S; Xing J; Liu K; Zhao Y; Stangis M; Jacho DP; Yildirim-Ayan ED; Gatto-Weis CM; Chen B; Li X
J Exp Clin Cancer Res; 2023 Oct; 42(1):264. PubMed ID: 37821954
[TBL] [Abstract][Full Text] [Related]
8. Hyperacetylation enhances the growth-inhibitory effect of all-trans retinoic acid by the restoration of retinoic acid receptor beta expression in head and neck squamous carcinoma (HNSCC) cells.
Whang YM; Choi EJ; Seo JH; Kim JS; Yoo YD; Kim YH
Cancer Chemother Pharmacol; 2005 Nov; 56(5):543-55. PubMed ID: 15959780
[TBL] [Abstract][Full Text] [Related]
9. The gene desert mammary carcinoma susceptibility locus Mcs1a regulates Nr2f1 modifying mammary epithelial cell differentiation and proliferation.
Smits BM; Haag JD; Rissman AI; Sharma D; Tran A; Schoenborn AA; Baird RC; Peiffer DS; Leinweber DQ; Muelbl MJ; Meilahn AL; Eichelberg MR; Leng N; Kendziorski C; John MC; Powers PA; Alexander CM; Gould MN
PLoS Genet; 2013 Jun; 9(6):e1003549. PubMed ID: 23785296
[TBL] [Abstract][Full Text] [Related]
10. 5-Azacytidine- and retinoic-acid-induced reprogramming of DCCs into dormancy suppresses metastasis via restored TGF-β-SMAD4 signaling.
Singh DK; Carcamo S; Farias EF; Hasson D; Zheng W; Sun D; Huang X; Cheung J; Nobre AR; Kale N; Sosa MS; Bernstein E; Aguirre-Ghiso JA
Cell Rep; 2023 Jun; 42(6):112560. PubMed ID: 37267946
[TBL] [Abstract][Full Text] [Related]
11. 5-Aza-2'-deoxycytidine induces retinoic acid receptor-beta(2) demethylation and growth inhibition in esophageal squamous carcinoma cells.
Liu Z; Zhang L; Ding F; Li J; Guo M; Li W; Wang Y; Yu Z; Zhan Q; Wu M; Liu Z
Cancer Lett; 2005 Dec; 230(2):271-83. PubMed ID: 16297713
[TBL] [Abstract][Full Text] [Related]
12. Identification and characterization of retinoic acid receptor beta2 target genes in F9 teratocarcinoma cells.
Zhuang Y; Faria TN; Chambon P; Gudas LJ
Mol Cancer Res; 2003 Jun; 1(8):619-30. PubMed ID: 12805409
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of retinoic acid-inducible transcription by COUP-TFI in human salivary gland adenocarcinoma cell line HSG.
Kyakumoto S; Ota M; Sato N
Biochem Cell Biol; 1999; 77(6):515-26. PubMed ID: 10668629
[TBL] [Abstract][Full Text] [Related]
14. The biology and clinical implications of prostate cancer dormancy and metastasis.
Morrissey C; Vessella RL; Lange PH; Lam HM
J Mol Med (Berl); 2016 Mar; 94(3):259-65. PubMed ID: 26489605
[TBL] [Abstract][Full Text] [Related]
15. A gene signature identified using a mouse model of androgen receptor-dependent prostate cancer predicts biochemical relapse in human disease.
Thompson VC; Day TK; Bianco-Miotto T; Selth LA; Han G; Thomas M; Buchanan G; Scher HI; Nelson CC; ; Greenberg NM; Butler LM; Tilley WD
Int J Cancer; 2012 Aug; 131(3):662-72. PubMed ID: 22275114
[TBL] [Abstract][Full Text] [Related]
16. HOXA5 acts directly downstream of retinoic acid receptor beta and contributes to retinoic acid-induced apoptosis and growth inhibition.
Chen H; Zhang H; Lee J; Liang X; Wu X; Zhu T; Lo PK; Zhang X; Sukumar S
Cancer Res; 2007 Sep; 67(17):8007-13. PubMed ID: 17804711
[TBL] [Abstract][Full Text] [Related]
17. Osteoblastic protein kinase D1 contributes to the prostate cancer cells dormancy via GAS6-circadian clock signaling.
Li G; Fan M; Zheng Z; Zhang Y; Zhang Z; Huang Z; Luo W; Zhao W; Lai X; Chen H; Zeng F; Deng F
Biochim Biophys Acta Mol Cell Res; 2022 Sep; 1869(9):119296. PubMed ID: 35595103
[TBL] [Abstract][Full Text] [Related]
18. Suppression of growth and tumorigenicity in the prostate tumor cell line M12 by overexpression of the transcription factor SOX9.
Drivdahl R; Haugk KH; Sprenger CC; Nelson PS; Tennant MK; Plymate SR
Oncogene; 2004 Jun; 23(26):4584-93. PubMed ID: 15077158
[TBL] [Abstract][Full Text] [Related]
19. Reactivation of tumor suppressor genes by the cardiovascular drugs hydralazine and procainamide and their potential use in cancer therapy.
Segura-Pacheco B; Trejo-Becerril C; Perez-Cardenas E; Taja-Chayeb L; Mariscal I; Chavez A; Acuña C; Salazar AM; Lizano M; Dueñas-Gonzalez A
Clin Cancer Res; 2003 May; 9(5):1596-603. PubMed ID: 12738711
[TBL] [Abstract][Full Text] [Related]
20. Endogenous reactivation of the RARbeta2 tumor suppressor gene epigenetically silenced in breast cancer.
Sirchia SM; Ren M; Pili R; Sironi E; Somenzi G; Ghidoni R; Toma S; Nicolò G; Sacchi N
Cancer Res; 2002 May; 62(9):2455-61. PubMed ID: 11980632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
